According to Zacks, “U.S. Physical Therapy, Inc. operates outpatient physical and occupational therapy clinics which provide post-operative care and treatment for a variety of orthopedic-related disorders and sports-related injuries. “
Other analysts also recently issued reports about the company. Jefferies Group set a $65.00 target price on U.S. Physical Therapy and gave the company a hold rating in a research note on Friday, August 5th. Barrington Research downgraded U.S. Physical Therapy from an outperform rating to a market perform rating in a research note on Friday, August 5th.
U.S. Physical Therapy (NYSE:USPH) traded down 1.53% during mid-day trading on Thursday, hitting $63.21. The company had a trading volume of 9,605 shares. U.S. Physical Therapy has a 52 week low of $43.18 and a 52 week high of $64.89. The firm’s 50 day moving average is $62.97 and its 200 day moving average is $57.81. The company has a market capitalization of $791.39 million, a price-to-earnings ratio of 32.58 and a beta of 0.72.
U.S. Physical Therapy (NYSE:USPH) last posted its quarterly earnings data on Thursday, August 4th. The company reported $0.57 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.02. U.S. Physical Therapy had a return on equity of 12.06% and a net margin of 6.95%. The company earned $90.40 million during the quarter, compared to analyst estimates of $90.01 million. During the same quarter last year, the company earned $0.51 EPS. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. On average, equities research analysts predict that U.S. Physical Therapy will post $1.99 EPS for the current year.
In other news, COO Glenn Mcdowell sold 4,047 shares of the firm’s stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $60.20, for a total value of $243,629.40. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Lawrance W. Mcafee sold 2,000 shares of the firm’s stock in a transaction on Friday, August 5th. The stock was sold at an average price of $59.60, for a total value of $119,200.00. The disclosure for this sale can be found here. Company insiders own 4.30% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. CT Mason increased its position in U.S. Physical Therapy by 1.1% in the third quarter. CT Mason now owns 47,749 shares of the company’s stock worth $2,994,000 after buying an additional 510 shares during the period. Mason Street Advisors LLC purchased a new position in U.S. Physical Therapy during the second quarter worth about $147,000. Schwab Charles Investment Management Inc. increased its position in U.S. Physical Therapy by 1.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 46,022 shares of the company’s stock worth $2,771,000 after buying an additional 810 shares during the period. Hillsdale Investment Management Inc. purchased a new position in U.S. Physical Therapy during the second quarter worth about $440,000. Finally, Fiera Capital Corp purchased a new position in U.S. Physical Therapy during the second quarter worth about $801,000. Hedge funds and other institutional investors own 98.33% of the company’s stock.
U.S. Physical Therapy Company Profile
U.S. Physical Therapy, Inc, through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care, and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers and neurological-related injuries.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for U.S. Physical Therapy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for U.S. Physical Therapy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.